

TTC36 (E-18): sc-244528

BACKGROUND

With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and disease association-dense chromosome. The chromosome 11-encoded *Atm* gene is important for regulation of cell cycle arrest and apoptosis following double strand DNA breaks. *Atm* mutation leads to the disorder known as ataxia-telangiectasia. The blood disorders Sickle cell anemia and β thalassemia are caused by HBB gene mutations. Wilms' tumors, WAGR syndrome and Denys-Drash syndrome are associated with mutations of the *WT1* gene. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are also associated with defects in chromosome 11.

REFERENCES

1. Grossfeld, P.D., et al. 2004. The 11q terminal deletion disorder: a prospective study of 110 cases. *Am. J. Med. Genet. A* 129A: 51-61.
2. Lousouarn, G., et al. 2006. KCNQ1 K⁺ channel-mediated cardiac channelopathies. *Methods Mol. Biol.* 337: 167-183.
3. Taylor, T.D., et al. 2006. Human chromosome 11 DNA sequence and analysis including novel gene identification. *Nature* 440: 497-500.
4. Zehelein, J., et al. 2006. Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. *J. Biol. Chem.* 281: 35397-35403.
5. Ataga, K.I., et al. 2007. β -thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. *Br. J. Haematol.* 139: 3-13.
6. Berger, A.C., et al. 2007. The subcellular localization of the Niemann-Pick type C proteins depends on the adaptor complex AP-3. *J. Cell Sci.* 120: 3640-3652.
7. Lee, J.H. and Paull, T.T. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. *Oncogene* 26: 7741-7748.
8. O'Connor, M.J., et al. 2007. Targeted cancer therapies based on the inhibition of DNA strand break repair. *Oncogene* 26: 7816-7824.
9. Kaste, S.C., et al. 2008. Wilms' tumour: prognostic factors, staging, therapy and late effects. *Pediatr. Radiol.* 38: 2-17.

CHROMOSOMAL LOCATION

Genetic locus: TTC36 (human) mapping to 11q23.3.

SOURCE

TTC36 (E-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of TTC36 of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-244528 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

TTC36 (E-18) is recommended for detection of TTC36 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.